North Carolina is currently home to 2644 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis
NCT06441266
Recruiting
The purpose of this research study is to test the ability of a mobile device application (MyCap) to collect patient information about their radiation skin rash in patients with head and neck cancer being treated with radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Radiation Dermatitis
Register for Updates
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT06352073
Recruiting
The purpose of this research study is to determine how well an FDA-approved drug, dupilumab, works to treat patients with severe strictures and active Eosinophilic Esophagitis (EoE). This is an open-label study, meaning everyone in the study will receive dupilumab. Participants will have a screening visit where they will complete surveys and undergo an endoscopy (EGD). Blood and biopsies (small tissue samples) will also be collected. If eligible and enrolled into the study, participants will re... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/30/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Eosinophilic Esophagitis, EoE
Register for Updates
AcoArt Litos PCB Below-the-knee Global Trial
NCT06330493
Recruiting
The objective of this study is to assess whether efficacy of the AcoArt Litos PCB is superior and whether safety of AcoArt Litos PCB is noninferior to the control device (FDA cleared PTA Balloon Catheter) regarding treatment of obstructions in the infrapopliteal arteries (located distal to the P3 segment of the popliteal artery and extending to the tibiotalar joint) in patients presenting with chronic limb-threatening ischemia (CLTI)(Rutherford 4-5)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: South Charlotte General & Vascular Surgery, Charlotte, North Carolina
Conditions: Chronic Limb-Threatening Ischemia
Register for Updates
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
NCT06071767
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Chapel Hill CRS, Chapel Hill, North Carolina
Conditions: HIV-1-infection
Register for Updates
Bone, Exercise, Alendronate, and Caloric Restriction
NCT05764733
Recruiting
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/30/2025
Locations: Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Conditions: Bone Loss
Register for Updates
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
Recruiting
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Metastatic Breast Cancer
Register for Updates
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
NCT05525663
Recruiting
The REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility disability during 6-month follow-up in patients hospitalized for heart failure and preserved ejection fraction (HFpEF), which is nearly unique to older persons, and for which there are few treatment options.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/30/2025
Locations: Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)
NCT05416333
Recruiting
The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hair growth cycle.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Wake Forest University Health Scieces, Winston-Salem, North Carolina
Conditions: Central Centrifugal Cicatricial Alopecia
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
NCT04421768
Recruiting
All physicians, nurses, and nurse midwives working on Labor and Delivery will be required to complete cervical exam simulation training. Data before and after institution of the training will be compared to determine if the training leads to less cervical exams during labor and increases consistency between examiners
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Delivery Problem, Cervix; Pregnancy, Pregnancy Related
Register for Updates
Prebiotic Galacto-oligosaccharide and Acute GVHD
NCT04373057
Recruiting
The purpose of this study is to determine whether the carbohydrate prebiotic (dietary supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria in the gut) and help prevent graft-versus host disease (GVHD) after allogeneic stem cell transplant. The study has two two parts. In phase 1, the best dose of GOS will be evaluated. In phase 2, using the best dose of GOS, participants will be randomized to receive GOS or a placebo (maltodextrin, a common food additive t... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/30/2025
Locations: Duke, Durham, North Carolina
Conditions: Acute GVHD
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/30/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates